Our cases with pulmonary alveolar proteinosis

Conclusions: Current evidence suggests that TAL is still standard therapy for PAP. However, inhaled GM-CSF therapy is an alternative for patients who do not benefit from TAL and / or patients with autoantibody positivity.

Source: European Respiratory Journal - November 19, 2018 Category: Respiratory Medicine Authors: Okumus, G., Bingol, Z., Öcal, G., Kiyan, E. Tags: Rare ILD/DPLD Source Type: research